Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jan 09, 2019
REUTERS: U.S. government says shutdown may slow resolution of CVS/Aetna court process

REUTERS: U.S. government says shutdown may slow resolution of CVS/Aetna court process

The Justice Department has said in a court filing that a partial government shutdown could delay its response to comments on pharmacy chain CVS Health Corp’s (CVS.N) purchase of health insurer Aetna, a necessary step in a court giving final approval to the deal. READ MORE...

Related Ticker: CVS

Momentum Indicator for CVS turns positive, indicating new upward trend

CVS saw its Momentum Indicator move above the 0 level on June 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in of 342 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 254 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CVS moved out of overbought territory on July 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 68 cases where CVS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CVS turned negative on July 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CVS broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.721) is normal, around the industry mean (4.990). P/E Ratio (45.820) is within average values for comparable stocks, (49.585). CVS's Projected Growth (PEG Ratio) (0.294) is slightly lower than the industry average of (1.408). CVS has a moderately high Dividend Yield (0.025) as compared to the industry average of (0.019). P/S Ratio (0.326) is also within normal values, averaging (0.682).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. CVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 72.43B. The market cap for tickers in the group ranges from 1.01M to 386.51B. UNH holds the highest valuation in this group at 386.51B. The lowest valued company is IHGP at 1.01M.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -1%. For the same Industry, the average monthly price growth was 14%, and the average quarterly price growth was 35%. CI experienced the highest price growth at 5%, while CLOV experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was -32%. For the same stocks of the Industry, the average monthly volume growth was -45% and the average quarterly volume growth was -33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 37
P/E Growth Rating: 45
Price Growth Rating: 22
SMR Rating: 81
Profit Risk Rating: 90
Seasonality Score: 0 (-100 ... +100)
Related Portfolios: CONSUMER STAPLES ETFs
View a ticker or compare two or three
CVS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

an integrated pharmacy health care provider

Industry ManagedHealthCare

Profile
Details
Industry
Drugstore Chains
Address
One CVS Drive
Phone
+1 401 765-1500
Employees
300000
Web
https://www.cvshealth.com
Interact to see
Advertisement
Aon plc (AON) reported third-quarter 2025 revenue of $3.997 billion, representing a 7% year-over-year increase with equal organic growth. Adjusted earnings per share came in at $3.05, exceeding expectations. In late November, Moody’s reaffirmed Aon’s Baa2 credit rating and revised the outlook to positive, citing reduced leverage following the NFP acquisition.
Air Products and Chemicals, Inc. (APD) entered the spotlight after announcing advanced discussions with Yara International on December 8 to collaborate on low-emission ammonia projects. While the strategic direction aligns with global decarbonization trends, uncertainty around execution and capital requirements triggered a 9.45% one-day decline in the stock.
Lockheed Martin and RTX Corporation are two of the most prominent names in the aerospace and defense industry, both positioned to benefit from heightened global security concerns and sustained U.S. military spending.
As 2025 winds down, the Savings Banks sector reflects a mix of stability, innovation, and AI-driven disruption. Among the most closely watched tickers—SOFI Technologies (SOFI), Ally Financial (ALLY), and PayPal Holdings (PYPL)—investors have witnessed contrasting stories of growth, valuation, and market perception.
Ondas Holdings (ONDS) is a wireless technology company focused on delivering secure, long-range communications for industrial Internet of Things (IoT) and data networking applications. Its solutions are built to support mission-critical operations across sectors such as rail, energy, maritime, infrastructure, and industrial automation.
Ciena’s growth is driven by expanding offerings in optical networking, network automation software, and 5G transport infrastructure, complemented by services designed to help customers modernize and future-proof their networks. Its evolving technology portfolio addresses the rising complexity, speed, and reliability requirements of today’s communications environment.
Marathon Digital Holdings (MARA) and Riot Platforms (RIOT) are two leading companies in the Bitcoin mining industry, each operating energy-intensive infrastructure to capitalize on cryptocurrency market cycles. This comparison is especially relevant amid ongoing Bitcoin price volatility and growing interest in digital assets and AI-related infrastructure.
Roivant Sciences has delivered strong year-to-date performance, with shares up roughly 82%, driven by encouraging pipeline developments and increased investment in high-potential subsidiaries such as Immunovant.
MP Materials Corp. (MP) and USA Rare Earth, Inc. (USAR) are central to the United States’ push to establish a secure, domestic supply of rare earth elements—materials critical to electric vehicles, renewable energy, and defense technologies. As geopolitical tensions and supply chain vulnerabilities intensify, these two companies offer distinct approaches to addressing U.S. dependence on foreign sources.
The Invesco QQQ Trust (NASDAQ: QQQ) remains one of the most closely followed ETFs worldwide, offering investors direct exposure to the NASDAQ-100 Index®. In the most recent data, QQQ has gained a notable +20.16% year-to-date, even as markets experienced bouts of elevated volatility.
Sidus Space has expanded its portfolio in 2025, focusing on satellite missions and supporting technologies to enhance space infrastructure. Key product advancements include the LizzieSat platforms, with multiple units progressing in design and manufacturing. LizzieSat-3 is set for launch no earlier than Q1 2025, building on prior missions to boost data capabilities for clients in Earth observation and communication.
As 2025 comes to a close, Dingdong (Cayman) Limited (DDL) continues to strengthen its position in China’s competitive fresh grocery e-commerce market. Operating from Shanghai, the company focuses on high-quality fresh produce, ready-to-eat meals, and daily essentials delivered directly to consumers. Throughout the year, Dingdong emphasized private-label expansion, supply-chain optimization, and fulfillment network growth—initiatives that supported improving quarterly performance and positioned the company for sustained momentum.
Pioneer Power's 2025 highlights include the expansion of its mobile power and charging footprint with new orders and partnerships; the launch of a new suite of e-Boost solutions for off-grid EV charging; the rebranding of HomeBoost as PowerCore with events in December; the introduction of PRYMUS in December; and a new five-year contract for network transformers with a regional utility provider.
An AI-driven comparison between Palantir (PLTR) and Oracle (ORCL) points to Palantir as the more compelling investment heading into 2026. The analysis highlights PLTR’s AI-native platforms, which enable real-time, data-driven decision-making across fast-growing sectors such as government, defense, and enterprise analytics.
An AI-driven comparison between D-Wave Quantum (QBTS) and IonQ (IONQ) points to IonQ as the stronger opportunity heading into 2026. The analysis highlights IONQ’s gate-based, trapped-ion quantum architecture, which supports a wide range of algorithms and positions the company for broader adoption across AI, simulation, and cryptography.
An AI-driven comparison of Rigetti Computing (RGTI) and D-Wave Quantum (QBTS) points to Rigetti as the more compelling opportunity heading into 2026. The analysis highlights RGTI’s gate-based quantum architecture, which supports universal quantum computing and a wide range of complex algorithms. While D-Wave remains a leader in quantum annealing for optimization problems, Rigetti’s full-stack, gate-based approach offers greater scalability and broader long-term applications.
An AI-driven comparison of Rigetti Computing (RGTI) and TeraWulf (WULF) points to TeraWulf as the more attractive investment heading into 2026. The analysis emphasizes WULF’s large-scale digital infrastructure supporting Bitcoin mining and high-performance computing (HPC), which generates immediate revenue in expanding digital asset and AI-driven markets.
An AI-driven comparison between Rocket Lab USA (RKLB) and Planet Labs (PL) identifies Rocket Lab as the more compelling investment heading into 2026. The analysis highlights RKLB’s vertically integrated space services and consistent launch performance, which position the company to benefit from rising demand for satellite deployment and space infrastructure.
An AI-driven comparison of Tempus AI (TEM) and Doximity (DOCS) points to Tempus AI as the more compelling investment opportunity heading into 2026. The analysis highlights TEM’s AI-powered precision medicine platform, which applies advanced analytics and genomic data to transform diagnostics and treatment in oncology and cardiology.